PDF下载 ( 1609 KB)
PI3K/Akt/mTOR signal transduction pathway and digestive system tumors
-
-
[1]Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism[J]. Cell, 2006, 124 (2) ∶ 471-484. [2]OldhamS, Montagne J, Radimerski T, et al.Genetic and biochemi-cal characterization of dTOR, the Drosophila homolog of the target ofrapamycin[J].Genes Dev, 2000, 14 (4) ∶2689-2694. [3]Fingar DC, Salama S, Tsou C, et al.Mammalian cell size is con-trolled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E[J].Genes Dev, 2002, 16 (12) ∶1472-1487. [4]Gingras AC, Raught B, Sonenberg N.mTOR signaling to translation[J]. Curr Top Microbiol Immunol, 2004, 279∶ 169-197. [5]Hay N, Sonenberg N. Upstream and downstream of mTOR[J]. Genes Dev, 2004, 18 (16) ∶ 1926-1945. [6]Tsang C K, Zheng X F. TOR-in (g) the nucleus[J]. Cell Cycle, 2007, 6 (1) ∶25-29. [7]Guertin D A, Sabatini D M. An expanding role for mTOR in cancer[J]. Trends Mol Med, 2005, 11 (8) ∶ 353-361. [8]Schmelzle T, Hall MN.TOR, a central controller of cell growth[J]. Cell, 2000, 103 (2) ∶253-262. [9]Kim S, Wong P, Coulombe PA.A keratin cytoskeletal protein regu-lates protein synthesis and epithelial cell growth[J].Nature, 2006, 441 (7091) ∶362-365. [10]Huang S, Houghton PJ.Targeting mTOR signaling for cancer therapy[J]. Curr Opin Pharmacol, 2003, 3 (4) ∶371-377. [11]Vignot S, Faivre S, Aguirre D, et al.mTOR-targeted therapy of cancer with rapamycin derivatives[J]. Ann Oncol, 2005, 16 (4) ∶525-537. [12]Abraham RT. Identification of TOR signaling complexes:more TORC for the cell growth engine[J]. Cell, 2002, 111 (1) ∶9-12. [13]Gingras AC, Raught B, Sonenberg N, et al.Regulation of translation ini-tiation by FRAP/mTOR[J].Genes Dev, 2001, 15 (7) ∶807-826. [14]Jacinto E, Hall MN.TOR signaling in bugs, brain and brawn[J]. Nat Rev Mol Cell Biol, 2003, 4 (2) ∶117-126. [15]Katso R, Okkenhaug K, Ahmadi K, et al.Cellular function of phos-phoinositide 3-kinases:implications for development, homeostasis, andcancer[J].Annu Rev Cell Dev Biol, 2001, 17 (4) ∶615-675. [16]Aoki M, Batista O, Bellacosa A, et al.The Akt kinase:molecular de-terminants of oncogenicity[J].Proc Natl Acad Sci US A, 1998, 95 (3) ∶14950-14955. [17]Cantrell DA.Phosphoinositide 3-kinase signalling pathways[J]. J Cell Sci, 2001, 114 (6) ∶1439-1445. [18]Samuels Y, Diaz LA, Sehlnidt-Kittler O, et al.Mutant PIK3CApromotes cell growth and invasion of human cancer cells[J].Canc-er Cell, 2005, 7 (2) ∶561-573. [19]Lee JW, Soung YH, Kim SY, et al.PIK3CAgene is frequently muta-ted in breast carcinomas and hepatocellular carcinomas[J].Onco-gene, 2005, 24 (4) ∶1477-1480. [20]Hartmann C, Bartel G, Gehlhaar C, et al.PIK3CAmutations in glio-blastoma multiforme[J].Acta Neuropathol, 2005, 109 (5) ∶639-642. [21]Levine DA, Bogomolniy F, Yee CJ, et al.Frequent mutation of the PIK3CA gene in ovarian and breast cancers[J]. Clin Cancer Res, 2005, 11 (2) ∶2875-2878. [22]Bader AG, Kang S, Vogt PK.Cancer-specific mutations in PIK3CA are oncogenic in vivo[J]. Proc Natl Acad Sci U S A, 2006, 103 (2) ∶1475-1479. [23]Carson JD, Van Aller G, Lehr R, et al.Effects of oncogenic P110 al-pha subunit mutations on the lipid kinase activity of phosphoinosit-ide3-kinase[J].Biochem J, 2008, 409 (6) ∶519-524. [24]Fingar DC, Richardson CJ, Tee AR, et al.mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/Eukaryotic translation initiation factor 4E[J]. Mol Cell Biol, 2004, 24 (1) ∶200-216. [25]Hay N, Sonenberg N.Upstream and downstream of mTOR[J]. Genes Dev, 2004, 18 (2) ∶1926-1945. [26]Gingras AC, Raught B, Sonenberg N, et al.Regulation of transla-tion initiation by FRAP/mTOR[J].Genes Dev, 2001, 15 (7) ∶807-826. [27]Fingar DC, Blenis J.Target of rapamycin (TOR) : an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression[J]. Oncogene, 2004, 23 (18) ∶ 3151-3171. [28]Proud CG.Regulation of mammalian translation factors by nutrients[J]. Eur J Biochem, 2002, 269 (8) ∶5338-5349. [29]Hay N, Sonenberg N.Upstream and downstream of mTOR[J]. Genes Dev, 2004, 18 (5) ∶1926-1945. [30]Wullschleger S, Loewith R, Hall MN.TOR signaling in growth and metabolism[J]. Cell, 2006, 124 (7) ∶471-484. [31]Eguchi S, Tokunaga C, Hidayat S, et al.Different roles for the TOSand RAIP motifs of the translation regulator protein 4E-BP1 in theassociation with raptor and phosphorylation by mTOR in the regula-tion of cell size[J].Genes Cells, 2006, 11 (1) ∶757-766. [32]Rebholz H, Panasyuk G, Fenton T, et al.Receptor association and tyrosine phosphorylation of S6 kinases[J]. FEBS J, 2006, 273 (2) ∶2023-2036. [33]Phin S, Kupferwasser D, Lam J, et al.Mutational analysis of riboso-mal S6 kinase 2 shows differential regulation of its kinase activityfrom that of ribosomal S6 kinase 1[J].Biochem J, 2003, 373 (3) ∶583-591. [34]Pene F, Claessens YE, Muller O, et al.Role of the phosphatidyli-nositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in theproliferation and apoptosis in multiple myeloma[J].Oncogene, 2002, 21 (6) ∶6587-6597. [35]Hay N, Sonenberg N.Upstream and downstream of mTOR[J]. Genes Dev, 2004, 18 (16) ∶1926-1945. [36]Fingar DC, Blenis J. Target of rapamycin (TOR) : an integrator of nutrient and growth factorsignals and coordinator of cell growth and cell cycle progression[J]. Oncogene, 2004, 23 (18) ∶ 3151-3171. [37]Suzuki Y, Toquenaga Y. Effects of information and group structure on evolution of altruism: analysis of two-score model by covariance and contextual analyses[J]. J Theor Bio l, 2005, 232 (2) ∶ 191-201. [38]Zhang H, Bajraszewski N, Wu E, et al. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR[J]. J Clin Invest, 2007, 117 (3) ∶ 730-738. [39]Panner A, James CD, Berger MS, et al. mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells[J]. Mol Cell Bio l, 2005, 25 (20) ∶ 8809-8823. [40]Herberser B, Puhalla H, Lehnert M, et al.Activated manunalian tar-get of Rapamycin is an adverse prognostie factor in patients with bil-iary tract adenocarcinoma[J].Clin Cancer Res, 2007, 13 (16) ∶4795-4799. [41]Law BK.Rapamycin:an anti-cancer immunosuppressant?[J]. Crit Rev Oncol Hematol, 2005, 56 (l) ∶47-60. [42]Suzuki Y, Toquenaga Y. Effects of information and group structure on evolution of altruism:analysis of two-score model by covariance and contextual analyses[J]. J Theor Biol, 2005, 232 (2) ∶191-201. [43]Shaw RJ, Bardeesy N, Manning BD, et al.The LKBl tumor suppres-sor negatively regulates MTOR signaling[J].Cancer Cell, 2004, 6 (l) ∶91-99. [44]Jimeno A, Kulesaza P, Cusatis G, et al.Pharmacodynamic-guided, modified continuous reassessment method (mCRM) -based, dose finding study of rapamycin in adults patientswith solid tumors[J]. ProcAm Soc Clin Onco l, 2006, 24 (4) ∶ 125. [45]Sharon BC, Penelope M, Alexander M, et al.Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells[J]. J SurgRes, 2007, 138 (3) ∶ 37-44. [46]Amato RJ, Misellati A, Khan M, et al. A phase II trial of RAD001 in patients with metastatic renal cell carcinoma[J]. J Clin Oncol, 2006, 24 (A4530) ∶ 18. [47]Mita MM, Rowinsky EK, Goldston ML, et al.Phase I, pharmacoki-netic (PK) , and pharmacodynamic (PD) study of AP23573, anmTOR inhibitor, administered IV daily X 5 every other week in pa-tients (pts) with refractory or advanced malignancies[J].Clin On-col, 2004, 30 (3) ∶76. -
本文二维码
计量
- 文章访问数: 3443
- HTML全文浏览量: 26
- PDF下载量: 802
- 被引次数: 0
下载:
